Biological designs on a big scale

摘要

In the world of biologies, Medlmmune has one of the most robust pipelines. The company currently has approximately 100 biologies in R&D; including 16 in clinical development and 11 in preclinical stage. The challenge of having a robust product pipeline is the need for operational flexibility to manufacture a diverse group of products with a wide range of titres. To enable production of forthcoming products, the company chose to build and license a flexible, large-scale mammalian cell culture-based production facility adjacent to its existing Frederick Manufacturing Center, Building 636, in Maryland, US. The new facility, Building 633, will initially house 337,000ft2 of administrative, production, warehouse, lab, and utility space.